CAC
BLU

Cowen and Company’s BELLUS Health Inc. BLU Stock Holding History

Cowen and Company’s Portfolio BLU Stock Details BLU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,625,883
Closed -$16.7M – 549
2020
Q2 		$16.7M Buy
1,625,883
+1,544,233
+1,891% +$15.7M 2.78% 5
2020
Q1 		$815K Buy
+81,650
New +$728K 0.19% 101

Other funds holding BLU

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Cowen and Company's BLU Position: Q3 2020 in Review

Cowen and Company sold out of BELLUS Health Inc. (BLU) in Q3 2020, closing a stake of 1,625,883 shares — an estimated $16.7M sold.

Cowen and Company first reported a position in BLU in Q1 2020 and held it in 2 quarters. The position peaked at $16.7M in Q2 2020. 50 funds tracked by Wall St. Rank hold BLU as of Q3 2020.

  • Cowen and Company reported no remaining BELLUS Health Inc. position as of Q3 2020 after selling out during the quarter.
  • Cowen and Company sold 1,625,883 BELLUS Health Inc. shares in Q3 2020, an estimated $16.7M.
  • Cowen and Company first reported a position in BELLUS Health Inc. in Q1 2020 and held it in 2 quarters.
  • Cowen and Company's BELLUS Health Inc. position peaked at $16.7M in Q2 2020.
  • 50 funds tracked by Wall St. Rank held BELLUS Health Inc. as of Q3 2020.

Based on Cowen and Company's 13F filing for Q3 2020, filed 3 Nov 2020.